In addition, targeted drugs against LRP2 and NKAIN4 may also improve the immune tolerance of cancer cells, thereby reducing the proliferation, invasion and migration capabilities of cancer cells, and improving the prognosis of patients. Here, LRP2 is linked to cancer.